Back to Newsroom

Cyclacel Pharmaceuticals to Present at the 30th Annual ROTH Conference

BERKELEY HEIGHTS, N.J., March 06, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases, announced today that the Company will present at the 2018 30th Annual ROTH Conference being held March 11- 14, 2018 at the Ritz Carlton, Laguna Niguel, California. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and its progress in key programs.